MicroRNA-related polymorphisms in apoptosis pathway genes are predictive of clinical outcome in patients with limited disease small cell lung cancer
Metrics: PDF 1879 views | HTML 1992 views | ?
Wei Jiang1, Nan Bi1, Wen-Jue Zhang1, Li-Hong Wu1, Li-Pin Liu1, Yu Men1, Jing-Bo Wang1, Jun Liang1, Zhou-Guang Hui1, Zong-Mei Zhou1, Lu-Hua Wang1
1Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Lu-Hua Wang, e-mail: [email protected]
Keywords: small cell lung cancer, limited-disease, single nucleotide polymorphisms, microRNA, apoptosis pathway
Received: November 26, 2015 Accepted: February 21, 2016 Published: March 16, 2016
We examined the impact of single nucleotide polymorphisms (SNPs) at miRNA binding sites in the 3′-UTRs of genes in the apoptosis pathway on the prognosis of patients with limited disease-small cell lung cancer (LD-SCLC). Twelve tagSNPs in seven genes were genotyped using blood samples from 146 LD-SCLC patients treated with chemoradiotherapy. Cox proportional hazard regression models and recursive partitioning analysis were performed to identify SNPs significantly associated with overall survival. Three SNPs, CASP8: rs1045494 (C > T), PIK3R1: rs3756668 (A > G) and CASP7: rs4353229 (T > C), were associated with longer overall survival in LD-SCLC patients after chemoradiotherapy. The adjusted hazard ratios (95% confidence intervals) were 0.480 (0.258–0.894), 0.405 (0.173–0.947) and 0.446 (0.247–0.802), respectively, and remained significant after multiple comparison correction. Moreover, subset analysis showed these SNPs were still predictive of overall survival in stage III patients. Recursive partitioning analysis enabled patients to be classified into three risk subgroups based on unfavorable genotype combinations of the rs1045494 and rs4353229 SNPs. These findings suggest miRNA-related polymorphisms in the apoptosis pathway may be useful biomarkers for selection of LD-SCLC patients likely to benefit from chemoradiotherapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.